The Sleep Disorders Channel is supported through educational grants from Alkermes and Takeda.
VJNeurology is an independent medical education platform. Channel supporters have no influence over the production of content.
SLEEP 2026 | Evolving understanding of orexin deficiency in narcolepsy type 1 and the impact of orexin agonists
Nancy Foldvary-Schaefer, DO, Cleveland Clinic, Cleveland, OH, discusses the evolving understanding of orexin deficiency in narcolepsy type 1 and the potential impact of orexin agonists. Prof. Foldvary-Schaefer highlights how these agents may offer a transformative change in care by potentially restoring function and improving quality of life. This interview took place at the 40th annual meeting of the Associated Professional Sleep Societies (APSS) in Baltimore, MD.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
